Publication of List of Manufacturers Granted Licence for the Manufacture of Therapeutic Goods

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, addresses the regulation of therapeutic goods, including their manufacture, to ensure public health and safety. This Act was introduced to fill the need for a comprehensive legislative framework governing the quality, safety, and efficacy of therapeutic goods available in Australia. The policy objective of the Act is to protect the health and safety of Australians by regulating the supply and advertising of therapeutic goods, ensuring they meet necessary standards before entering the market. The Therapeutic Goods Administration (TGA), as a part of the Department of Health, is responsible for administering this Act, including the issuance of manufacturing licences as detailed in the Gazette publication. The publication of the list of manufacturers granted a licence is a critical step in maintaining transparency and accountability in the manufacture of therapeutic goods within the country.

Scope and Application

The Therapeutic Goods Act 1989 applies to persons or entities engaged in the manufacture, supply, or importation of therapeutic goods in Australia, as well as to the advertising, sponsorship, or promotion of these goods. This legislation operates on a national level, thereby extending its reach across all states and territories within the Commonwealth of Australia. The Act mandates that certain therapeutic goods require a licence for their manufacture, ensuring that the products meet necessary safety, quality, and efficacy standards before they are made available to the public. The Act also provides for the regulation of therapeutic goods throughout their lifecycle, including post-market surveillance to ensure continued compliance. While the Therapeutic Goods Act 1989 sets out the overarching framework, specific details and additional regulations may be outlined in subordinate instruments or regulations, which can further extend or restrict the application of the Act. Exemptions and exclusions, such as for certain low-risk goods or specific therapeutic activities, are specified within the Act and its accompanying regulations, allowing for a nuanced approach to regulation depending on the nature and risk profile of the goods involved.

Key Provisions

The Therapeutic Goods Act 1989, in section 38, outlines the process for the grant of a licence to manufacture therapeutic goods. This act has been utilised to grant a manufacturing licence to several entities, as specified in the notice published by the Therapeutic Goods Administration (TGA). Specifically, Cell Therapies Pty Ltd has been granted a licence with the number MI-2015-LI-10786-1, Eris Pharmaceuticals (Australia) Pty Ltd with MI-2018-LI-05521-1, Symbion Pty Ltd T/A Healthcare Logistics (Australia) with MI-2017-LI-11851-1, and AFG Quality and Regulatory Consulting Pty Ltd with MI-2018-LI-00645-1. These licences allow the named entities to manufacture therapeutic goods under the oversight of the TGA. Entities that receive a manufacturing licence under the Therapeutic Goods Act 1989 are subject to a number of obligations and requirements. These include maintaining appropriate manufacturing practices as per the standards set out in the Therapeutic Goods Regulations 1990, ensuring that any therapeutic goods produced are safe and of high quality, and complying with all applicable Australian regulations. The licence holders must also keep accurate records of their manufacturing processes and ensure that their facilities are inspected and approved by the TGA. The Therapeutic Goods Act 1989 contains provisions that address offences and penalties for non-compliance with the Act and its regulations. Section 9 of the Act provides that any person who contravenes the Act may be subject to a civil penalty, which can include fines of up to $222,200 for an individual and $1,111,000 for a body corporate. Additionally, section 32DA allows for the imposition of criminal penalties, including fines and imprisonment, for serious offences such as manufacturing counterfeit therapeutic goods or selling therapeutic goods that are dangerous to health. The maximum penalties for such offences can be significant, with fines up to $5.5 million and imprisonment for up to 10 years for individuals, and higher for body corporates. The Therapeutic Goods Act 1989 also includes provisions for the revocation of licences in cases of non-compliance or where the licence holder is found to be unfit to hold a licence. Section 38A allows the Secretary to revoke a manufacturing licence if it is determined that the licence holder does not meet the requirements of the Act or if the licence holder has committed an offence under the Act. The revocation of a licence can have serious consequences for the entity, potentially resulting in the cessation of manufacturing operations and significant financial loss. Therefore, it is crucial for licence holders to adhere strictly to the requirements and obligations set out in the Act and its regulations.